Other languages Summit Therapeutics Inc.

Equities

SMMT

US86627T1088

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
4.65 ^USD	-2.72%		+5.92%	+78.16%

May. 07	Citigroup Starts Summit Therapeutics With Buy Rating, $7 Price Target	MT
May. 01	Transcript : Summit Therapeutics Inc., Q1 2024 Earnings Call, May 01, 2024

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Summit Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 01
Summit Therapeutics Inc. Appoints Dr. Mostafa Ronaghi to Its Board of Directors	Apr. 11
Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed	Apr. 09
Illumina CFO Goswami to depart, Summit Therapeutics' Dhingra named successor	Apr. 09
Summit Therapeutics Appoints COO to Additional Role of CFO	Apr. 04
Summit Therapeutics Inc. Appoints Bhaskar Anand as Chief Accounting Officer, Head of Finance, to Serve as Its Principal Accounting Officer	Apr. 03
Pulse Biosciences Shares Fall After Q4 Results, Rights Issue Plans	Apr. 01
Summit Therapeutics Insider Bought Shares Worth $375,000, According to a Recent SEC Filing	Mar. 28
Summit Therapeutics Reports 23% Complete Response in Metastatic NSCL Cancer Drug Ivonescimab's Clinical Trials	Mar. 22
Summit Therapeutics Inc. Announces Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024	Mar. 22
Akeso Logs First-Ever Profit in 2023; Beats EPS Forecast	Mar. 18
Summit Therapeutics Inc. Announces That Data for Its Novel, Potential First-In-Class Investigational Bispecific Antibody, Ivonescimab, Will Be Presented At the 2024 European Lung Cancer Congress (Elcc 2024) in Prague, Czech Republic	Mar. 14
Akeso Books First-Ever Profit in 2023; Shares Fall 5%	Mar. 05
Top Midday Decliners	Feb. 20
Summit Therapeutics Files Mixed Securities Shelf	Feb. 20
Summit Therapeutics Q4 Loss Widens	Feb. 20
Summit Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 20
Summit Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 20
Summit Therapeutics Announces Updated Phase II Data for Ivonescimab At 42Nd Annual J.P. Morgan Healthcare Conference	Jan. 08
Summit Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Summit Therapeutics Inc.

Equities

SMMT

US86627T1088

Other languages

Filters